Eisai inaugurates new US HQ as closely watched FDA Alzheimer's decision draws near

Eisai officially launched its new U.S. headquarters just as the Japanese pharma looks to expand its commercial presence with an Aduhelm follow-up in Alzheimer’s disease by “building trust with the public.”